Search
glulisine (Apidra)
Tradename: Apidra (FDA-approved in 2004)
Indications: diabetes mellitus
Dosage:
- can mix with NPH
- draw glulisine into syring 1st, inject immediately
100 units/mL, 10 mL vials, 3 mL cartridge
Pharmacokinetics:
1) rapid-acting insulin, onset 10-15 minutes
2) peak 1-1.5 hours
3) duration 3-5 hours Presumptively a recombinant protein.
Notes: Manufacturer: Aventis
Interactions
drug adverse effects of hypoglycemic agents
General
short-acting insulin
recombinant protein; chimer
References
- Prescriber's Letter 12(2): 2005
New Drugs Approved by the FDA in 2004
Detail-Document#: 210216
(subscription needed) http://www.prescribersletter.com
- Prescriber's Letter 13(3): 2006
Detail-Document#: 220309
Comparison of Insulins
(subscription needed) http://www.prescribersletter.com